202 related articles for article (PubMed ID: 17147969)
1. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
Fox LP
J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969
[TBL] [Abstract][Full Text] [Related]
2. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
3. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
7. Nail toxicity induced by cancer chemotherapy.
Gilbar P; Hain A; Peereboom VM
J Oncol Pharm Pract; 2009 Sep; 15(3):143-55. PubMed ID: 19171552
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
10. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
11. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
12. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
Lee SL; Tan BS; Chan LC
J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
White KJ; Roydhouse JK; Scott K
Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
[TBL] [Abstract][Full Text] [Related]
14. Drug-related nail disease.
Piraccini BM; Alessandrini A
Clin Dermatol; 2013; 31(5):618-26. PubMed ID: 24079591
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic toxicities of targeted anticancer therapies.
Balagula Y; Lacouture ME; Cotliar JA
J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
[TBL] [Abstract][Full Text] [Related]
16. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
Lacouture ME; Lai SE
Br J Dermatol; 2006 Oct; 155(4):852-4. PubMed ID: 16965448
[No Abstract] [Full Text] [Related]
17. Drug reactions affecting the nail unit: diagnosis and management.
Piraccini BM; Iorizzo M
Dermatol Clin; 2007 Apr; 25(2):215-21, vii. PubMed ID: 17430758
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
20. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Dainichi T; Tanaka M; Tsuruta N; Furue M; Noda K
Dermatology; 2003; 207(3):324-5. PubMed ID: 14571080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
